SEC For	m 4 FORM -	4 U	NITEI	O STAT	ES S	SEC						N	GE C	OM	MISS	ON	J			
						Washington, D.C. 20549												OMB APPROVAL		
to Section 16. Form 4 or Form 5 obligations may continue. See					T OF CHANGES IN BENEFICIAL OWNE													er: verage burd sponse:	3235-0287 en 0.5	
	(-)				or Se	ction 3	30(h) o	f the Ir	vestmer	nt Cor	npany Act	of 1	.940							
1. Name and Address of Reporting Person [*] <u>LEWIS JOEL</u>				GA	2. Issuer Name and Ticker or Trading Symbol <u>GALECTIN THERAPEUTICS INC</u> [GALT]							(Check all applicable X Director			10% Owner					
(Last) (First) (Middle)													X Officer (give titl below)				Other (below)	specity		
C/O GALECTIN THERAPEUTICS INC. 4960 PEACHTREE INDUSTRIAL BLVD., STE 240					3. Date of Earliest Transaction (Month/Day/Year) 03/31/2022										President	t and	CEO			
4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)												
(Street) NORCROSS GA 30071													X F	,						
(City) (State) (Zip)														·						
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed o	of, d	or Ben	efici	ally O	wne	d			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				Execution Date,			3. Transaction Code (Instr. 8)4. Securiti Disposed 5)								es ally Following	Forn (D) o	vnership n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount		(A) or (D)	Price	Transaction(a)		tion(s)			(1150.4)
Common Stock ⁽¹⁾ 03/31/				2022				Α		10,87	0	Α	\$1.	1.61 458,870 ⁽²⁾		870 ⁽²⁾		D		
		Tal		Derivati (e.g., pu												ned				
1. Title of Derivative Security (Instr. 3)	Title of 2. 3. Transaction 3A. Deemed erivative Conversion Date Execution Date, ccurity or Exercise (Month/Day/Year) if any			Transaction of Code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			A S U D S	7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		8. Price of Derivative Security (Instr. 5) r.		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
													or	mount						

Explanation of Responses:

1. Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units ("DSUs") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2023 and (iii) fifty percent shall be settled on March 1, 2024.

Date

Exercisable

2. Represents shares underlying DSUs and Common Stock.

Jack	W.	Callicutt,	<u>by power of</u>	
				03/31/2022

attorney

of

Shares

Title

Expiration Date

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code V

(A) (D)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.